EN
登录

CVS与eMed合作开展GLP-1福利模式

CVS, eMed partner on GLP-1 benefit model

Becker's Hospital Review 等信源发布 2026-02-17 22:25

可切换为仅中文


Telehealth company eMed has partnered with CVS Caremark to offer a GLP-1 benefit model that lets employers subsidize weight loss medications without covering the full cost,

远程医疗公司eMed已与CVS Caremark合作,推出了一种GLP-1福利模式,允许雇主在不承担全部费用的情况下补贴减肥药物。

Axios

Axios

reported Feb. 16.

2月16日报道。

The arrangement allows eligible employees to purchase GLP-1s online through eMed and receive weight management services including side effect management, weekly check-ins and blood testing. Employers can decide how much of the cost to subsidize, the report said.

该安排允许符合条件的员工通过eMed在线购买GLP-1,并获得包括副作用管理、每周检查和血液检测在内的体重管理服务。报道称,雇主可以决定补贴多少费用。

CVS Caremark manages prescription benefits for up to 30 million people and views the collaboration as another way to expand GLP-1 access.

CVS Caremark 为多达 3000 万人管理处方福利,并将此次合作视为扩大 GLP-1 获取渠道的另一种方式。

“We offer multiple solutions to best meet our clients’ diverse needs — based on how they’d like to manage the GLP-1 class both on benefit and off benefit (where eMed focuses),” CVS said in a statement shared with

“我们提供多种解决方案,以最好地满足客户的不同需求——基于他们希望如何在福利范围内和福利范围外(eMed重点关注的领域)管理GLP-1类药物,”CVS在一份声明中表示。

Becker’s

贝克的

. “All have the ability to prescribe, but the primary focus is a personalized approach to GLP-1 and obesity management.”

“所有人都有能力开处方,但主要关注的是针对GLP-1和肥胖管理的个性化方法。”

Recommended OnDemand Webinar

推荐的按需网络研讨会

GLP-1 therapies continue to reshape chronic disease treatment, triggering regulatory updates, new clinical findings and intensifying competition across the pharmaceutical…

GLP-1疗法继续重塑慢性疾病治疗,引发监管更新、新的临床发现,并加剧制药行业竞争…

Patients with endometrial hyperplasia or benign uterine pathology had a 66% reduced risk of developing endometrial cancer when treated with…

当用...治疗时,患有子宫内膜增生或良性子宫病理的患者患子宫内膜癌的风险降低了66%。

Two days after offering compounded versions of oral Wegovy, telehealth company Hims & Hers pulled the product from its platform…

在提供口服Wegovy的复方版本两天后,远程医疗公司Hims & Hers将其从平台上撤下…